-
摘要:
近年来，免疫治疗在非小细胞肺癌领域取得突破性进展，重塑了肺癌治疗格局，但是随着免疫治疗在临床的广泛应用，其产生的免疫相关性不良事件越来越受到重视，其中免疫性肺炎作为最受关注的不良反应之一，影响疾病治疗进程和疗效，严重者甚至危及生命。免疫性肺炎发病机制复杂、临床表现多样化，亟需加强对免疫性肺炎的认知能力。免疫性肺炎的治疗手段有限，更多的治疗药物正在探索中。因此，本文对非小细胞肺癌免疫性肺炎的研究进展进行综述。
Abstract:In recent years, immunotherapy has made a breakthrough in the field of non-small cell lung cancer, reshaping the pattern of lung cancer treatment. However, with the wide application of immunotherapy in clinical practice, immune-related adverse events have attracted increasing attention. Immune pneumonia, as one of the immune-related toxic side effects of greatest concern, affects the treatment process and curative effect and can be a threat to life in serious cases. Given that immune pneumonia has a complicated pathogenesis and diverse clinical manifestations, strengthening the understanding of immune pneumonia is urgently needed. The treatment of immune pneumonia is limited, and additional therapeutic medicines are still awaiting exploration. Therefore, this paper summarizes the progress of the research on immune pneumonia in the treatment of non-small cell lung cancer.
-
0 引言
子宫内膜癌是在北美和欧洲最常见的女性恶性肿瘤，近年来我国的发病率明显增加，发病人群年轻化[1]。子宫内膜癌的发病机制目前尚未完全明确，随着研究的深入，越来越清晰地认识到子宫内膜癌是多种因素协同交叉作用、具有不同遗传和分子特征的一类疾病[2-3]。根据肿瘤发病机制与雌激素依赖相关性，将其分为Ⅰ型和Ⅱ型，80%以上为Ⅰ型子宫内膜癌。遗传易感性是导致个体对相同致癌因素敏感度不一致的重要因素，某些雌激素代谢通路中关键酶可以改变体内雌激素或外源性雌激素及其代谢产物的水平。基因多态性与酶活性有关，雌激素代谢酶基因多态性可能导致子宫内膜癌发病易感性差异[4]。本研究利用SNP分型检测技术，探索雌激素代谢关键酶CYP1B1、CYP1A1和NQO1基因的单核苷酸多态性（single nucleotide polymorphisms, SNPs）位点分布频率与Ⅰ型子宫内膜癌易感性之间关系，以期对Ⅰ型子宫内膜癌的易感人群进行筛查。
1 资料与方法
1.1 临床资料
抽取我院2014年3月—2016年10月收治的经病理诊断为子宫内膜样腺癌的103例患者和同期子宫内膜正常的100例其他疾病患者静脉外周全血2~3 ml，作为检测标本。病例和对照组均取得患者的知情同意并详细询问病史，包括初潮年龄、生育状况、绝经年龄、孕产次数、内科并发症及肿瘤家族史。测量身高与体重，并计算体质指数（body mass index, BMI），测量血压，采集静脉血化验空腹血糖（FPG）及血脂、肿瘤标志物[5-6]。年龄31~78岁，平均（51.15±9.69）岁，子宫内膜癌组平均年龄（54.77±8.21）岁，对照组为（46.95±9.65）岁。
1.2 方法
1.2.1 确定候选基因及其SNPs位点
由于Ⅰ型子宫内膜癌为雌激素依赖性肿瘤，结合相关文献报道，在美国国家生物技术信息中心（National Center for Biotechnology Information, NCBI）人类基因组数据库中选择与雌激素代谢相关的关键酶CYP1A1、CYP1B1，具有抗癌突变的依赖还原型辅酶Ⅰ/Ⅱ醌氧化还原酶1（quinone oxido-reductase1, NQO1）3个基因，选取与代谢酶活性密切相关且杂合度大于10%的SNPs位点进行基因型分析。
1.2.2 引物设计合成
利用引物设计软件premier 5.0，在含SNPs的DNA序列上设计PCR引物，并将设计的引物进行引物的同源性比较，选出同源性最小而Tm值和G/C比值合适的引物作为PCR反应引物，所扩增片段应包含要检测的SNPs位点，其位置尽可能设计在PCR扩增片段的中部。
1.2.3 检测方法
使用DNA提取试剂盒（DP304-03）从外周血中提取DNA，进行预扩增，琼脂糖凝胶电泳检测DNA完整性。根据设计引物模板，进行延伸反应及延伸产物纯化。PCR扩增反应体系总体积为50 μl，内含5 μl 10×PCR缓冲液，3 μl 25 mmol/L MgCl2溶液，5 μl 2 mmol/L dNTP混合物，1.25 U Taq DNA聚合酶，0.5 μmol/L引物及100g的基因组DNA。反应在MJ公司PTC-100 PCR反应仪中进行。PCR循环条件为95℃预变性10 min，然后94℃变性30 s，60℃复性30 s，72℃延伸30 s，反应40个循环后，72℃再延伸10 min。扩增产物用2%的琼脂糖凝胶电泳检测，4℃保存。PCR产物经纯化后作为测序模板，用Big-Dye末端荧光标记试剂盒进行测序反应，测序反应产物经纯化后在ABI公司3730XL测序仪上进行测序电泳，用Gene codes公司的Sequencer4.2对测序结果进行分析。
1.3 统计学方法
采用SPSS18.0软件对实验数据进行统计学分析，用χ2检验和多因素Logistic回归模型分析各基因型在两组人群中的分布差异及其与子宫内膜癌临床病理特征的相关性，P < 0.05为差异有统计学意义。
2 结果
2.1 多因素回归分析
CYP1B1基因SNPs位点rs111888224因无碱基改变未纳入统计，rs1056836、rs2551188、rs10916在研究人群中均存在多态性，但分布频率差异无统计学意义；rs1056836 C、G基因分布频率差异有统计学意义（P=0.0454）。
CYP1A1基因SNP位点rs4646421在研究人群中存在CT、CC、TT多态性。与CT型相比，CC型为保护基因型，OR=0.479（95%CI: 0.255~0.899），差异有统计学意义（P=0.0219），其C、T基因分布频率差异有统计学意义（P=0.0041），见表 1。
表 1 基因型/等位基因在Ⅰ型子宫内膜癌患者中的分布(n(%))Table 1 Genotype/alleles distributions in typeⅠendometrial carcinoma cases (n(%))
2.2 CYP1A1基因rs4646421位点多态性与Ⅰ型子宫内膜癌危险因素的分层分析
对CYP1A1基因rs4646421位点不同基因型与Ⅰ型子宫内膜癌的危险因素相关性进行分层比较，发现在年龄 > 60岁、BMI≥25、绝经延迟、并发高血压的个体中，携带CT+TT突变基因型将增加罹患Ⅰ型子宫内膜癌的风险（P < 0.05），见表 2。
表 2 发病危险因素与基因型分布的关系(n(%))Table 2 Association between risk factors and genotypes distributions of SNP(rs4646421) in CYP1A1 (n(%))
3 讨论
雌激素分布在细胞内外表面，通过雌激素受体的核内结合蛋白在靶细胞中保持高亲和力和特异性。涉及雌激素生物合成和代谢的基因的多态性是雌激素受体阳性恶性肿瘤的潜在危险因素，有几种细胞色素P450（CYP）酶参与雌激素的氧化代谢途径[7]。CYP1A1和CYP1B1是代谢产生2-羟基-4-羟基雌激素代谢物的基本酶[8-9]，在不同人群中不仅存在多态性，并且在性激素相关组织中的表达高于细胞色素P450超家族的其他成员，其基因多态性与乳腺癌、子宫肌瘤、子宫内膜异位症、宫颈癌等疾病风险相关[10-14]。
CYP1A1基因定位于人类染色体15q22-24，编码由512个氨基酸组成的蛋白质，是细胞色素P450家族中高诱导成员。CYP1A1酶的激活参与内源性和外源性化合物的氧化作用，催化多环芳香族碳氢化合物转化为酚与环氧化合物。一些酚类和环氧化合物可与DNA结合形成加合物，最终转化为致癌物、二醇环氧化物，通过环氧化物水解酶与一些抗肿瘤药物发生耐药，并增加个体肿瘤风险[9, 15]。本研究结果显示CYP1A1基因SNP位点rs4646421在子宫内膜癌人群中存在CT、CC、TT多态性，与携带CT基因型相比，携带CC基因型的个体罹患子宫内膜癌的风险较小，携带T等位基因的个体子宫内膜癌的发病风险高于C等位基因携带者。与携带CC基因型相比，携带TC+TT基因型在年龄 > 60岁、BMI≥25、绝经延迟（超过52岁）、合并高血压的女性中Ⅰ型子宫内膜癌的发病风险增加。
CYP1B1基因位于染色体2q21-22，其单核苷酸多态性SNP总数有353个，目前研究较多的是SNPrs1056836，其mRNA发生1294位碱基胞嘧啶（cytosine, C）变异为鸟嘌呤（guanine, G），使DNA两条链形成野生CC型，杂合CG型和变异GG型3种基因型，即基因多态性。这种改变导致第三外显子432密码子的碱基由CTG变异为GTG，由其编码的亮氨酸（leucine, Leu）变异为缬氨酸（valine, Val），导致CYP1B1酶蛋白功能的改变[16]。CYP1B1通过多方面影响肿瘤的易感性和预后，在胰岛素抵抗中产生作用，突变型表达的酶之蛋白质表现出更强的激活癌前物质活性，或影响睾酮的6β-羟化作用及性激素的激活代谢等[17-18]。
本研究中CYP1B1基因SNP rs2551188、rs10916两个位点在人群中存在多态性，但分布频率无统计学差异；rs1056836在正常子宫内膜组与子宫内膜癌两组间的基因型分布频率无差异，但发生更多的碱基胞嘧啶变异为鸟嘌呤，可能会使罹患子宫内膜癌的风险增加，以往文献中发现对于单个位点基因突变的表现为阴性结论时，多个位点联合的单倍体基因型研究却往往能得到阳性结论，似乎预示着CYP1B1基因在分子遗传学上有一定的倾向性[16-19]，但其与肿瘤易感性及预后的机制问题还存在着诸多争议与疑惑，有待于进一步研究。
NQO1是一种重要的化学致癌物质代谢酶，具有抗癌作用，可使内源性及外源性醌类化合物通过电子还原反应变成低毒性的氢醌类物质，再转化为水溶性化合物排出体外，降低了细胞发生突变及癌变的概率。如果位点发生突变，使原位编码的氨基酸发生改变，将会导致该酶活性减弱或完全丧失，降低解毒功能且不能维护细胞稳定，增加某些易感个体细胞发生癌变[20]。报道显示NQO1蛋白高表达在卵巢癌、乳腺癌、结直肠癌等肿瘤中，与临床分期晚、分化程度差和淋巴结转移等临床特征有关[21-22]，本研究选择的SNP位点rs45488899和rs1800566虽在两组间均存在基因多态性，但分布频率不具有差异性，因此认为这两个SNP位点与Ⅰ型子宫内膜癌的发生无显著相关性。
本研究通过基因表达谱差异的分析，推测CYP1A1基因rs4646421位点的多态性在Ⅰ型子宫内膜癌的发生发展中起着重要作用，可作为进行高危人群筛查的基因位点，还可以突变的基因型为基础，采取针对性的基因靶向治疗，或者通过修正基因突变谱来改善其预后。但是，基因多态性受复杂的遗传、环境因素、种族等的影响，并与样本量的大小有关，必须经过大样本试验来进一步明确基因多态性与子宫内膜癌易感性之间的基因环境交互作用及具体机制。
Competing interests: The authors declare that they have no competing interests.利益冲突声明：所有作者均声明不存在利益冲突。作者贡献：王天鸣：文献收集及论文构思、撰写与修改张良：论文修改程颖：论文撰写指导及审阅 -
[1] Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade[J]. N Engl J Med, 2018, 378(2): 158-168. doi: 10.1056/NEJMra1703481
[2] Zhong L, Altan M, Shannon VR, et al. Immune-Related Adverse Events: Pneumonitis[J]. Adv Exp Med Biol, 2020, 1244: 255-269.
[3] Ma K, Lu Y, Jiang S, et al. The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis[J]. Front Pharmacol, 2018, 9: 1430. doi: 10.3389/fphar.2018.01430
[4] Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis[J]. JAMA Oncol, 2016, 2(12): 1607-1616. doi: 10.1001/jamaoncol.2016.2453
[5] 杨勇豪, 王阿香, 高全立. PD-1单抗所致免疫相关性肺炎诊治经验[J]. 中华医学杂志, 2019, 99(36): 2855-2858. doi: 10.3760/cma.j.issn.0376-2491.2019.36.012 Yang YH, Wang AX, Gao QL. Experience in diagnosis and treatment of immune-associated pneumonia caused by PD-1 monoclonal antibody[J]. Zhonghua Yi Xue Za Zhi, 2019, 99(36): 2855-2858. doi: 10.3760/cma.j.issn.0376-2491.2019.36.012
[6] Sonpavde GP, Grivas P, Lin Y, et al. Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials[J]. Future Oncol, 2021, 17(19): 2545-2558. doi: 10.2217/fon-2020-1222
[7] Esfahani K, Elkrief A, Calabrese C, et al. Moving towards personalized treatments of immune-related adverse events[J]. Nat Rev Clin Oncol, 2020, 17(8): 504-515. doi: 10.1038/s41571-020-0352-8
[8] Xiao Y, Yu S, Zhu B, et al. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance[J]. J Exp Med, 2014, 211(5): 943-959. doi: 10.1084/jem.20130790
[9] Voong KR, Hazell S, Hu C, et al. MA 09.08 receipt of chest radiation and immune-related pneumonitis inpatients with NSCLC treated with anti-PD-1/PD-L1[J]. J Thorac Oncol, 2017, 12(11): S1837. doi: 10.1016/j.jtho.2017.09.529
[10] Zhang C, Gao F, Jin S, et al. Checkpoint inhibitor pneumonitis in Chinese lung cancer patients: clinical characteristics and risk factors[J]. Ann Palliat Med, 2020, 9(6): 3957-3965. doi: 10.21037/apm-20-1823
[11] Moda M, Saito H, Kato T, et al. Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer[J]. Thorac Cancer, 2020, 11(12): 3576-3584. doi: 10.1111/1759-7714.13703
[12] Ahn MJ, Cho BC, Ou X, et al. Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial[J]. J Thorac Oncol, 2022, 17(5): 718-723. doi: 10.1016/j.jtho.2022.01.012
[13] Oxnard GR, Yang JC, Yu H, et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer[J]. Ann Oncol, 2020, 31(4): 507-516. doi: 10.1016/j.annonc.2020.01.013
[14] Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage Ⅲ Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2017, 377(20): 1919-1929. doi: 10.1056/NEJMoa1709937
[15] Jabbour SK, Lee KH, Frost N, et al. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage Ⅲ Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial[J]. JAMA Oncol, 2021, 7(9): 1-9.
[16] Peters S, Felip E, Dafni U, et al. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage Ⅲ non-small cell lung cancer-The ETOP NICOLAS trial[J]. Lung Cancer, 2019, 133: 83-87. doi: 10.1016/j.lungcan.2019.05.001
[17] 周蓉, 李丹叶, 杨萌, 等. 免疫检查点抑制剂导致免疫相关性肺炎的诊治进展[J]. 中日友好医院学报, 2019, 33(2): 114-116. https://www.cnki.com.cn/Article/CJFDTOTAL-ZRYH201902014.htm Zhou R, Li DY, Yang M, et al. Progress of diagnosis and treatment of immune-associated pneumonia caused by immune checkpoint inhibitors[J]. Zhong Ri You Hao Yi Yuan Xue Bao, 2019, 33(2): 114-116. https://www.cnki.com.cn/Article/CJFDTOTAL-ZRYH201902014.htm
[18] 薛鹏, 徐芃芃, 毛昀, 等. 非小细胞肺癌免疫检查点抑制剂相关性肺炎研究进展[J]. 中国肿瘤, 2019, 28(5): 367-372. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201905009.htm Xue P, Xu PP, Mao Y, et al. Research Progress on Checkpoint Inhibitor-related Pneumonitis in Non-small Cell Lung Cancer[J]. Zhongguo Zhong Liu, 2019, 28(5): 367-372. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201905009.htm
[19] Naidoo J, Wang X, Woo KM, et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy[J]. J Clin Oncol, 2017, 35(7): 709-717. doi: 10.1200/JCO.2016.68.2005
[20] Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J[J]. Eur Respir J, 2017, 50(2): 1700050. doi: 10.1183/13993003.00050-2017
[21] Nishino M, Ramaiya NH, Awad MM, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course[J]. Clin Cancer Res, 2016, 22(24): 6051-6060. doi: 10.1158/1078-0432.CCR-16-1320
[22] Larsen BT, Chae JM, Dixit AS, et al. Clinical and histopathologic features of immune checkpoint inhibitorrelated pneumonitis[J]. Am J Surg Pathol, 2019, 43(10): 1331-1340. doi: 10.1097/PAS.0000000000001298
[23] Fujisawa Y, Yoshino K, Otsuka A, et al. Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab[J]. J Dermatol Sci, 2017, 88(2): 225-231. doi: 10.1016/j.jdermsci.2017.07.007
[24] Zhou J, Zhao J, Jia Q, et al. Peripheral blood autoantibodies against to tumor-associated antigen predict clinical outcome to immune checkpoint inhibitor-based treatment in advanced non-small cell lung cancer[J]. Front Oncol, 2021, 11: 625578. doi: 10.3389/fonc.2021.625578
[25] Ke W, Zhang L, Dai Y. The role of IL-6 in immunotherapy of nonsmall cell lung cancer (NSCLC) with immune-related adverse events (irAEs)[J]. Thorac Cancer, 2020, 11(4): 835-839. doi: 10.1111/1759-7714.13341
[26] 彭智, 袁家佳, 王正航, 等. ASCO/NCCN免疫治疗毒性管理指南解读[J]. 肿瘤综合治疗电子杂志, 2018, 4(2): 38-47. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLZD201802013.htm Peng Z, Yuan JJ, Wang ZH, et al. Comments on ASCO/NCCN management guidelines of toxicities from immunotherapy[J]. Zhong Liu Zong He Zhi Liao Dian Zi Za Zhi, 2018, 4(2): 38-47. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLZD201802013.htm
[27] Brahmer JR, Lacchetti C, Schneider BJ, et al. National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2018, 36(17): 1714-1768. doi: 10.1200/JCO.2017.77.6385
[28] Xie XH, Deng HY, Lin XQ, et al. Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer[J]. Front Oncol, 2021, 11: 673877. doi: 10.3389/fonc.2021.673877
[29] 于海明, 李进英, 于兰, 等. PD-1单抗导致免疫检查点抑制剂相关肺炎1例——吡非尼酮治疗的安全性和有效性[J]. 中国肺癌杂志, 2021, 24(7): 519-525. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ202107012.htm Yu HM, Li JY, Yu L, et al. A Case Report of Checkpoint Inhibitor Pneumonitis Caused by PD-1 Antibody-Safety and Effectiveness of Pirfenidone[J]. Zhongguo Fei Ai Za Zhi, 2021, 24(7): 519-525. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ202107012.htm
[30] 胡少丹, 仕丽, 王檀, 等. 王檀教授基于虚寒病机辨证治疗间质性肺疾病的临床经验浅析[J]. 中国中医药现代远程教育, 2020, 18(1): 42-44. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYY202001018.htm Hu SD, Shi L, Wang T, et al. Discussion on the Clinical Experience of Professor Wang Tan in the Treatment of Interstitial Lung Disease Based on Syndrome Differentiation of Deficient Cold Pathogenesis[J]. Zhongguo Zhong Yi Yao Xian Dai Yuan Cheng Jiao Yu, 2020, 18(1): 42-44. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYY202001018.htm
[31] 赵东凯, 杨桂仙. 助阳通痹法联合肺康复治疗间质性肺疾病30例临床观察及运动耐量改善情况评价[J]. 中国中医药现代远程教育, 2017, 15(22): 89-90. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYY201722039.htm Zhao DK, Yang GX. Clinical Observation and Improvement of Exercise Tolerance of Interstitial Lung Disease with Promoting Yang to Promote Obstruction Method Combined with Lung Rehabilitation for 30 Cases[J]. Zhongguo Zhong Yi Yao Xian Dai Yuan Cheng Jiao Yu, 2017, 15(22): 89-90. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYY201722039.htm
[32] 王春娥, 王辛秋. 晁恩祥治疗肺间质纤维化经验小结[J]. 福建中医药, 2018, 49(4): 58-59. https://www.cnki.com.cn/Article/CJFDTOTAL-FJZY201804023.htm Wang CE, Wang XQ. Summary of Chao Enxiang's experience in treating pulmonary interstitial fibrosis[J]. Fujian Zhong Yi Yao, 2018, 49(4): 58-59. https://www.cnki.com.cn/Article/CJFDTOTAL-FJZY201804023.htm
[33] 王玉光, 周平安, 刘清泉. 肺痹证治新诠[J]. 中国中医基础医学杂志, 2002, 8(7): 6-7. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC200207003.htm Wang YG, Zhou PG, Liu QQ. A new interpretation of the treatment of pulmonary arthralgia[J]. Zhongguo Zhong Yi Ji Chu Yi Xue Za Zhi, 2002, 8(7): 6-7. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC200207003.htm
[34] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)免疫检查点抑制剂相关的毒性管理指南2021[M]. 北京: 人民卫生出版社, 2021. Chinese Society of Clinical Oncology Guidelines Working Committee. Chinese Society of Clinical Oncology (CSCO) Toxicity Management Guidelines related to immune checkpoint inhibitors 2021[M]. Beijing: People's Medical Publishing House, 2021.
[35] Pollack MH, Betof A, Dearden H, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma[J]. Ann Oncol, 2018, 29(1): 250-255.
[36] Santini FC, Rizvi H, Plodkowski AJ, et al. Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC[J]. Cancer Immunol Res, 2018, 6(9): 1093-1099.
[37] Mouri A, Kaira K, Yamaguchi O, et al. Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer[J]. Cancer Chemother Pharmacol, 2019, 84(4): 873-880. http://www.xueshufan.com/publication/2969781963
下载:
计量
- 文章访问数: 1529
- HTML全文浏览量: 521
- PDF下载量: 1374
